retatrutide drug clinical trials weight loss New GLP-1 obesity drug, retatrutide, shows added benefits Retatrutide Peptide: The Breakthrough Triple-Hormone – Retatrutide for weight loss: Study

- Uneven skin tone

While large-scale studies are still ongoing, initial research has shown encouraging results: Direct Anti-Inflammatory Action: These drugs can reduce inflammation independently of weight loss by blocking specific cellular pathways

Current clinical evidence suggests GLP-1 receptor agonists like semaglutide have limited passage into breast milk, yet many lactating women remain uncertain about whether these medications are truly safe for their nursing infants

Compounded semaglutide is not FDA-approved as a finished drug product, but it is legally produced under federal and state oversight when sourced from registered 503B facilities